Results for 'strategic alliances ADC'
Content Type: All
Sorted by: Relevance
Showing 41 to 50 results of 4839
Whitepaper
ADC Therapeutics Drives Productivity with Labguru
ADC Therapeutics develops proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.
News
NBE Announces Validation of its SMAC-Technology for ADC Development
Successful validation of SMAC™-Technology at World ADC summit 2014 in Frankfurt, Germany.
News
Galapagos and Roche Expand COPD Alliance
Partners increase the number of antibody targets in the alliance.
News
Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance
Under the terms of the agreement, Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects.
News
Ablynx and Boehringer Ingelheim Announce Major Global Strategic Alliance
The alliance is aimed to discover, develop and commercialize up to 10 different Nanobody® therapeutics.
News
Carbogen Amcis AG Makes Capital Investments in ADC
New ADC capabilities benefit oncology innovators.
News
XenoGesis and Juniper Pharma Services Strengthen Alliance
Campanies extend strategic alliance in early drug development services.
News
Seattle Genetics and Genmab Enter into New ADC Collaboration
New ADC program will target AXL expressed on multiple tumor types.
News
VivaMab and ADC Therapeutics Announce Antibody Licensing Deal
Licensing deal for novel ADC candidate to target hematologic cancers.
News
GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory Diseases
The alliance leverages Archemix’s expertise in the discovery and development of Aptamers and provides GSK with an option to license product candidates.
Advertisement
